https://novapharmanews.com/us/news/excipient-world-conference-daily-roundup 2026-05-04T20:02:13.697Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T20:02:13.689Z Excipient World Conference: Key Highlights and Industry Trends https://novapharmanews.com/uploads/articles/excipient-world-conference-daily-roundup.webp Excipient World Conference: Key Highlights and Industry Trends https://novapharmanews.com/us/news/APHL-2026-annual-meeting-day-1-highlights 2026-05-04T19:52:29.241Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T16:00:35.928Z APHL 2026 Annual Meeting: Day 1 Highlights https://novapharmanews.com/uploads/articles/APHL-2026-annual-meeting-day-1-highlights.webp APHL 2026 Annual Meeting: Day 1 Highlights https://novapharmanews.com/us/news/aphl-2026-day-1-roundup 2026-05-04T20:12:48.857Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T12:00:31.547Z APHL 2026: Day 1 Highlights and Key Takeaways https://novapharmanews.com/uploads/articles/aphl-2026-day-1-roundup.webp APHL 2026: Day 1 Highlights and Key Takeaways https://novapharmanews.com/eu/news/swiss-biotech-day-daily-roundup 2026-05-04T20:14:33.171Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T08:01:51.242Z Swiss Biotech Day: Key Takeaways and Industry Trends https://novapharmanews.com/uploads/articles/swiss-biotech-day-daily-roundup.webp Swiss Biotech Day: Key Takeaways and Industry Trends https://novapharmanews.com/apac/news/fda-approves-auvelity-new-mdd-treatment 2026-05-04T12:48:55.588Z hourly 0.9 NovaPharmaNews en 2026-05-04T07:08:39.207Z FDA Approves Auvelity: A New Option for MDD https://novapharmanews.com/uploads/articles/fda-approves-auvelity-new-mdd-treatment.webp FDA Approves Auvelity: A New Option for MDD https://novapharmanews.com/apac/news/sun-pharma-organon-partnership-india 2026-05-04T12:49:12.653Z hourly 0.9 NovaPharmaNews en 2026-05-04T07:08:09.439Z Sun Pharma Organon Partnership to Expand Access to Key Medicines https://novapharmanews.com/uploads/articles/sun-pharma-organon-partnership-india.webp Sun Pharma Organon Partnership to Expand Access to Key Medicines https://novapharmanews.com/eu/news/fda-approves-auvelity-mdd-axsome-therapeutics 2026-05-04T12:48:55.544Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T07:05:54.602Z FDA Approves Auvelity for MDD: Axsome Therapeutics Scores Win https://novapharmanews.com/uploads/articles/fda-approves-auvelity-mdd-axsome-therapeutics.webp FDA Approves Auvelity for MDD: Axsome Therapeutics Scores Win https://novapharmanews.com/eu/news/purdue-pharma-shutdown-oxycontin-settlement 2026-05-04T12:49:12.317Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T07:04:18.946Z Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations https://novapharmanews.com/uploads/articles/purdue-pharma-shutdown-oxycontin-settlement.webp Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations https://novapharmanews.com/us/news/fda-approves-palazestrant-pfizer-arvinas-breast-cancer-drug 2026-05-04T13:26:05.858Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T07:02:27.732Z FDA Approves Palazestrant for Breast Cancer Amidst Data Concerns https://novapharmanews.com/uploads/articles/fda-approves-palazestrant-pfizer-arvinas-breast-cancer-drug.webp FDA Approves Palazestrant for Breast Cancer Amidst Data Concerns https://novapharmanews.com/eu/news/eular-2026-immutep-imp761-phase-1-preview 2026-05-04T20:09:36.011Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T05:03:13.771Z EULAR 2026: Immutep's IMP761 Phase I Data Preview https://novapharmanews.com/uploads/articles/eular-2026-immutep-imp761-phase-1-preview.webp EULAR 2026: Immutep's IMP761 Phase I Data Preview https://novapharmanews.com/us/news/thma-pharmacy-growth-priorities-2026 2026-05-04T14:40:59.829Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T05:02:27.663Z THMA Pharmacy Growth Priorities 2026: Key Insights for CPOs https://novapharmanews.com/uploads/articles/thma-pharmacy-growth-priorities-2026.webp THMA Pharmacy Growth Priorities 2026: Key Insights for CPOs https://novapharmanews.com/us/news/cphi-americas-2026-pharma-manufacturing-trends 2026-05-04T12:49:12.169Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T05:00:41.745Z CPhI Americas 2026: Pharma Manufacturing Trends in Philadelphia https://novapharmanews.com/uploads/articles/cphi-americas-2026-pharma-manufacturing-trends.webp CPhI Americas 2026: Pharma Manufacturing Trends in Philadelphia https://novapharmanews.com/us/news/ipec-americas-annual-meeting-daily-roundup 2026-05-04T20:01:19.418Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:02:03.608Z IPEC Americas Annual Meeting: Key Takeaways for Pharma https://novapharmanews.com/uploads/articles/ipec-americas-annual-meeting-daily-roundup.webp IPEC Americas Annual Meeting: Key Takeaways for Pharma https://novapharmanews.com/us/news/excipient-world-conference-day-1-highlights 2026-05-04T16:01:28.292Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:01:18.901Z Excipient World Conference: Day 1 Highlights https://novapharmanews.com/uploads/articles/excipient-world-conference-day-1-highlights.webp Excipient World Conference: Day 1 Highlights https://novapharmanews.com/us/news/aphl-2026-annual-day-1-roundup 2026-05-04T20:00:31.511Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:00:32.252Z APHL 2026 Annual Meeting: Key Takeaways from Day 1 https://novapharmanews.com/uploads/articles/aphl-2026-annual-day-1-roundup.webp APHL 2026 Annual Meeting: Key Takeaways from Day 1 https://novapharmanews.com/apac/news/ucb-acquires-candid-therapeutics-2-2-billion-t-cell-engager-autoimmune 2026-05-04T12:49:12.654Z hourly 0.9 NovaPharmaNews en 2026-05-04T03:03:42.696Z UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases https://novapharmanews.com/uploads/articles/ucb-acquires-candid-therapeutics-2-2-billion-t-cell-engager-autoimmune.webp UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases https://novapharmanews.com/eu/news/novelty-nobility-agc-biologics-bispecific-antibody-manufacturing-partnership 2026-05-04T12:49:12.260Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T03:02:58.961Z Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing https://novapharmanews.com/uploads/articles/novelty-nobility-agc-biologics-bispecific-antibody-manufacturing-partnership.webp Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing https://novapharmanews.com/eu/news/smartee-denti-technology-mandibular-repositioning-eas-congress-2026 2026-05-04T12:52:21.371Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T03:02:39.548Z Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026 https://novapharmanews.com/uploads/articles/smartee-denti-technology-mandibular-repositioning-eas-congress-2026.webp Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026 https://novapharmanews.com/us/news/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment 2026-05-04T20:13:24.267Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:02:18.090Z XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/uploads/articles/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment.webp XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/us/news/mirum-pharmaceuticals-vistas-volixibat-primary-sclerosing-cholangitis-results-may-2026 2026-05-04T12:50:10.147Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:56.836Z Mirum Pharmaceuticals VISTAS Study Results for Volixibat in Primary Sclerosing Cholangitis Due May 4, 2026 https://novapharmanews.com/uploads/articles/mirum-pharmaceuticals-vistas-volixibat-primary-sclerosing-cholangitis-results-may-2026.webp Mirum Pharmaceuticals VISTAS Study Results for Volixibat in Primary Sclerosing Cholangitis Due May 4, 2026 https://novapharmanews.com/us/news/everads-therapy-suprachoroidal-injector-clinical-data-ophthalmology-science 2026-05-04T12:50:10.542Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:31.010Z Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science https://novapharmanews.com/uploads/articles/everads-therapy-suprachoroidal-injector-clinical-data-ophthalmology-science.webp Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science https://novapharmanews.com/us/news/ucb-acquires-candid-therapeutics-autoimmune-deal 2026-05-04T14:00:17.214Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:05.077Z UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal https://novapharmanews.com/uploads/articles/ucb-acquires-candid-therapeutics-autoimmune-deal.webp UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal https://novapharmanews.com/us/news/spinogenix-tazbentetol-neuroprotective-glaucoma-diabetic-retinopathy-arvo-2026 2026-05-04T20:13:02.633Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:00:41.363Z Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026 https://novapharmanews.com/uploads/articles/spinogenix-tazbentetol-neuroprotective-glaucoma-diabetic-retinopathy-arvo-2026.webp Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026 https://novapharmanews.com/us/news/niktimvo-axatilimab-approved-australia-chronic-gvhd-treatment 2026-05-04T12:50:10.913Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:00:20.396Z NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment https://novapharmanews.com/uploads/articles/niktimvo-axatilimab-approved-australia-chronic-gvhd-treatment.webp NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment https://novapharmanews.com/us/news/ipec-annual-meeting-2026-no-pharma-news 2026-05-04T12:49:29.867Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:04:53.441Z IPEC Annual Meeting 2026: No Pharma News Today https://novapharmanews.com/uploads/articles/ipec-annual-meeting-2026-no-pharma-news.webp IPEC Annual Meeting 2026: No Pharma News Today https://novapharmanews.com/eu/news/swiss-biotech-day-2026-ai-oncology-microbiome 2026-05-04T12:49:41.664Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T00:03:42.558Z Swiss Biotech Day 2026: AI, Oncology, Microbiome Highlights https://novapharmanews.com/uploads/articles/swiss-biotech-day-2026-ai-oncology-microbiome.webp Swiss Biotech Day 2026: AI, Oncology, Microbiome Highlights https://novapharmanews.com/us/news/excipient-world-conference-2026-daily-roundup 2026-05-04T12:50:11.435Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:02:59.839Z Excipient World Conference 2026: No Pharma Breaking News https://novapharmanews.com/uploads/articles/excipient-world-conference-2026-daily-roundup.webp Excipient World Conference 2026: No Pharma Breaking News https://novapharmanews.com/us/news/aphl-2026-annual-meeting-opens-public-health-lab-focus 2026-05-04T12:50:11.471Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:00:53.404Z APHL 2026 Annual Meeting Opens: Public Health Lab Focus https://novapharmanews.com/uploads/articles/aphl-2026-annual-meeting-opens-public-health-lab-focus.webp APHL 2026 Annual Meeting Opens: Public Health Lab Focus https://novapharmanews.com/apac/news/fda-approves-auvelity-mdd-new-antidepressant 2026-05-04T15:20:23.588Z hourly 0.9 NovaPharmaNews en 2026-05-03T07:07:55.125Z FDA Approves Auvelity for MDD: A New Antidepressant Option https://novapharmanews.com/uploads/articles/fda-approves-auvelity-mdd-new-antidepressant.webp FDA Approves Auvelity for MDD: A New Antidepressant Option https://novapharmanews.com/eu/news/purdue-pharma-dissolution-approved-opioid-crisis 2026-05-04T19:12:27.254Z hourly 0.9 NovaPharmaNews en-GB 2026-05-03T07:05:42.135Z Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis https://novapharmanews.com/uploads/articles/purdue-pharma-dissolution-approved-opioid-crisis.webp Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis https://novapharmanews.com/eu/news/auvelity-fda-approval-axsome-therapeutics 2026-05-04T20:12:54.732Z hourly 0.9 NovaPharmaNews en-GB 2026-05-03T07:05:33.583Z Auvelity FDA Approval: New Hope for MDD Patients https://novapharmanews.com/uploads/articles/auvelity-fda-approval-axsome-therapeutics.webp Auvelity FDA Approval: New Hope for MDD Patients https://novapharmanews.com/us/news/axsome-fda-approval-alzheimers-agitation 2026-05-04T18:30:57.971Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T07:03:11.831Z Axsome FDA Approval for Alzheimer's Agitation Drug https://novapharmanews.com/uploads/articles/axsome-fda-approval-alzheimers-agitation.webp Axsome FDA Approval for Alzheimer's Agitation Drug https://novapharmanews.com/us/news/fda-approves-first-non-antipsychotic-dementia-agitation 2026-05-04T19:55:27.926Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T07:03:10.612Z FDA Approves First Non-Antipsychotic for Dementia Agitation https://novapharmanews.com/uploads/articles/fda-approves-first-non-antipsychotic-dementia-agitation.webp FDA Approves First Non-Antipsychotic for Dementia Agitation https://novapharmanews.com/apac/news/a2-milk-company-recalls-platinum-infant-formula-health-risk 2026-05-04T20:13:13.387Z hourly 0.9 NovaPharmaNews en 2026-05-03T03:04:15.228Z a2 Milk Company Recalls Three Batches of a2 Platinum Infant Formula Due to Health Risk Concerns https://novapharmanews.com/uploads/articles/a2-milk-company-recalls-platinum-infant-formula-health-risk.webp a2 Milk Company Recalls Three Batches of a2 Platinum Infant Formula Due to Health Risk Concerns https://novapharmanews.com/us/news/edwards-lifesciences-resilia-tissue-10-year-durability-aortic-valve-trial 2026-05-04T18:27:24.676Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T03:02:02.521Z Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in Pivotal Aortic Valve Trial https://novapharmanews.com/uploads/articles/edwards-lifesciences-resilia-tissue-10-year-durability-aortic-valve-trial.webp Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in Pivotal Aortic Valve Trial https://novapharmanews.com/us/news/biomarin-voxzogo-achondroplasia-long-term-data-pes-2026 2026-05-04T20:13:02.073Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T03:01:25.239Z BioMarin VOXZOGO Shows Long-Term Benefits for Achondroplasia in New Clinical Data at PES 2026 https://novapharmanews.com/uploads/articles/biomarin-voxzogo-achondroplasia-long-term-data-pes-2026.webp BioMarin VOXZOGO Shows Long-Term Benefits for Achondroplasia in New Clinical Data at PES 2026 https://novapharmanews.com/us/news/fda-approves-incyte-jakafi-xr-extended-release-myelofibrosis-polycythemia-vera 2026-05-04T19:49:26.448Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T03:00:36.859Z FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment https://novapharmanews.com/uploads/articles/fda-approves-incyte-jakafi-xr-extended-release-myelofibrosis-polycythemia-vera.webp FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment